---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-047090"
form_type: "8-K"
ticker: "IDXG"
cik: "0001054102"
company_name: "INTERPACE BIOSCIENCES, INC."
filed_at: "2026-10-15T10:10:45+00:00"
generated_at: "2026-10-15T10:15:09.125462+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Interpace Biosciences prelim Q3 2026 revenue $10.1M-$10.4M, up ~15-18% YoY

## Summary
- Preliminary unaudited Q3 2026 revenue expected to range $10.1 million to $10.4 million.
- Expected ~11%-14% quarter-over-quarter growth from $9.1 million in Q2 2026 and ~15%-18% year-over-year growth from $8.8 million in Q3 2025.
- Results are preliminary and subject to quarter-end closing procedures and review by the company's independent registered public accounting firm.
- Press release furnished as Exhibit 99.1; full Q3 2026 financial results expected to be reported at a later date.
- Release references a free writing prospectus related to an offering with a registration statement filed with the SEC.

## SEC filing metadata
- accession: 0001493152-26-047090
- form_type: 8-K
- ticker: IDXG
- cik: 0001054102
- company_name: INTERPACE BIOSCIENCES, INC.
- filed_at: 2026-10-15T10:10:45+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1054102/000149315226047090/0001493152-26-047090-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1054102/000149315226047090/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-047090
- JSON: https://secwatch.observer/filing/0001493152-26-047090.json
- Plain text: https://secwatch.observer/filing/0001493152-26-047090.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.